首页> 外文期刊>Diagnostic cytopathology >Negative Computer-Imaged ThinPrep Pap Test and Positive Hybrid Capture2 HPV Co-Testing Results: A Quality Assurance Review
【24h】

Negative Computer-Imaged ThinPrep Pap Test and Positive Hybrid Capture2 HPV Co-Testing Results: A Quality Assurance Review

机译:阴性的计算机成像ThinPrep子宫颈抹片检查和阳性Hybrid Capture2 HPV联合检测结果:质量保证审查

获取原文
获取原文并翻译 | 示例
       

摘要

Women >= 30 years of age with negative (-) Pap tests and positive (+) HPV co-test results have a higher prevalence and cumulative risk of developing high-grade cervical intraepithelial neoplasia (CIN 2+). Thus, the current management in these women is to repeat co-test in 12 months or immediate reflex genotyping for HPV16 or HPV 16/18. If genotyping is not an option, timely quality assurance (QA) rescreen of such Pap tests may be a valuable alternative. All ThinPrep Pap tests (TPPT) interpreted as negative for intra epithelial lesion (NILM) or NILM with reactive cellular changes (NILM/RCC) and a (+) high-risk HPV [Hybrid Capture 2 (HC2), Qiagen, Hilden, Germany] co-test result over a 45-month period (10/2009-06/2013) underwent monthly QA review. The TPPT were screened by the TP Imaging System [TIS, Hologic Inc., Bedford, MA]. Twenty five thousand six hundred and seventy five (18%) NILM and NILM/RCC TPPT of a total of 141,548 TPPT underwent HPV co-test. HPV test was (+) in 2,300 (8.9%) TPPT cases. HPV (+) cases by age group were <30 years, 486 (21%), and 30 years, 1,814 (79%). Upon QA review, 10 cases (0.4%) were reclassified, with significant findings in three cases in 30 years. Two cases showed high-grade squamous intraepithelial lesion (HSIL) on repeat Pap, and one case showed endocervical adenocarcinoma in situ (AIS) on biopsy. Timely QA review of HPV (+) Pap (-) co-tests is a valuable monitor. Ninety percentage of reclassified cases were in 30 age group and 70% were originally signed out by using TIS 22 Field of View (FOV) only. Three reclassified cases had significant findings on follow up (F/U). (c) 2015 Wiley Periodicals, Inc.
机译:> = 30岁的女性,巴氏试验阴性(-)和HPV阳性试验(+)阳性,患高级别宫颈上皮内瘤变(CIN 2+)的患病率和累积风险较高。因此,目前这些女性的治疗方法是在12个月内重复进行共同测试或立即对HPV16或HPV 16/18进行反射基因分型。如果无法进行基因分型,那么及时重新进行此类巴氏检测的质量保证(QA)筛选可能是一种有价值的选择。所有ThinPrep Pap测试(TPPT)均被解释为上皮内病变(NILM)或具有反应性细胞变化(NILM / RCC)和(+)高风险HPV [混合捕获2(HC2),NIAgen,希尔登,德国)的NILM阴性]在45个月内(10 / 2009-06 / 2013)的共同测试结果接受了每月质量检查。通过TP成像系统[TIS,Hologic Inc.,Bedford,MA]筛选TPPT。总共141,548 TPPT中的2 565(75%)NILM和NILM / RCC TPPT进行了HPV共同测试。在2,300(8.9%)TPPT病例中,HPV测试为(+)。按年龄组划分的HPV(+)病例分别为<30岁,486(21%)和30岁,1,814(79%)。经过质量检查后,重新分类了10例(0.4%),在30年中有3例得到了重大发现。 2例在重复Pap上显示高度鳞状上皮内病变(HSIL),1例在活检中显示原位宫颈内膜腺癌(AIS)。对HPV(+)子宫颈癌(-)共同测试进行及时的质量检查审查是有价值的监视器。 90%的重新分类病例属于30岁年龄组,而70%的原始病例仅使用TIS 22视野(FOV)退出。 3例重新分类的病例在随访(F / U)方面有重要发现。 (c)2015年威利期刊有限公司

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号